Chimerix (NASDAQ:CMRX) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Chimerix (NASDAQ:CMRX) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01, Zacks reports. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million.

Chimerix Stock Performance

NASDAQ CMRX traded up $0.04 on Friday, hitting $8.51. 1,508,704 shares of the stock were exchanged, compared to its average volume of 2,084,137. The stock has a fifty day moving average price of $5.24 and a two-hundred day moving average price of $2.77. The firm has a market capitalization of $764.91 million, a P/E ratio of -9.05 and a beta of 0.32. Chimerix has a 52-week low of $0.75 and a 52-week high of $8.52.

Analyst Ratings Changes

Several equities analysts have recently weighed in on CMRX shares. Jefferies Financial Group reissued a “hold” rating and set a $8.50 price target (down from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. Wedbush reissued a “neutral” rating and issued a $8.55 target price (up from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. HC Wainwright restated a “neutral” rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, StockNews.com began coverage on shares of Chimerix in a report on Saturday, March 15th. They set a “hold” rating for the company.

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the completion of the transaction, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold 20,760 shares of company stock valued at $91,175 over the last three months. 13.10% of the stock is owned by company insiders.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.